Endo International PLC (NASDAQ:ENDP) Receives $12.52 Average PT from Analysts
Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have earned an average recommendation of “Hold” from the twenty-three ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $10.25.
Several brokerages recently commented on ENDP. Citigroup cut their price target on shares of Thor Industries from $78.00 to $70.00 in a research note on Monday, June 17th. Gabelli reiterated a “hold” rating on shares of Endo International in a research note on Wednesday, March 27th. BidaskClub upgraded shares of Zai Lab from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Finally, Canaccord Genuity reiterated a “hold” rating and set a GBX 365 ($4.77) price target on shares of Crest Nicholson in a research note on Wednesday, May 15th.
NASDAQ:ENDP traded down $0.26 during midday trading on Tuesday, hitting $3.69. 5,008,557 shares of the company were exchanged, compared to its average volume of 3,770,808. The stock has a fifty day moving average of $4.40. Endo International has a fifty-two week low of $3.54 and a fifty-two week high of $18.50. The firm has a market capitalization of $882.10 million, a P/E ratio of 1.28 and a beta of 1.16.
In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of Endo International stock in a transaction on Monday, June 17th. The shares were sold at an average price of $3.93, for a total value of $137,357.43. Following the transaction, the director now directly owns 148,309 shares in the company, valued at $582,854.37. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ENDP. Signition LP acquired a new position in Endo International in the first quarter valued at $139,000. Neuburgh Advisers LLC increased its stake in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after purchasing an additional 3,036 shares during the period. Factorial Partners LLC purchased a new stake in shares of Endo International in the first quarter valued at about $193,000. First Quadrant L P CA boosted its holdings in shares of Endo International by 94.7% in the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock valued at $197,000 after acquiring an additional 11,926 shares in the last quarter. Finally, Flinton Capital Management LLC boosted its holdings in shares of Endo International by 13.9% in the fourth quarter. Flinton Capital Management LLC now owns 38,420 shares of the company’s stock valued at $280,000 after acquiring an additional 4,692 shares in the last quarter. Institutional investors own 93.59% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: How is net asset value different from market price?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.